|
EP2290071B1
(en)
|
2004-05-28 |
2014-12-31 |
Asuragen, Inc. |
Methods and compositions involving microRNA
|
|
CA2857881A1
(en)
|
2004-11-12 |
2006-12-28 |
Asuragen, Inc. |
Methods and compositions involving mirna and mirna inhibitor molecules
|
|
WO2006107826A2
(en)
|
2005-04-04 |
2006-10-12 |
The Board Of Regents Of The University Of Texas System |
Micro-rna's that regulate muscle cells
|
|
WO2008036765A2
(en)
*
|
2006-09-19 |
2008-03-27 |
Asuragen, Inc. |
Micrornas differentially expressed in pancreatic diseases and uses thereof
|
|
CA2685840C
(en)
*
|
2007-04-30 |
2016-12-13 |
The Ohio State University Research Foundation |
Methods for differentiating pancreatic cancer from normal pancreatic function and/or chronic pancreatitis
|
|
US8361714B2
(en)
|
2007-09-14 |
2013-01-29 |
Asuragen, Inc. |
Micrornas differentially expressed in cervical cancer and uses thereof
|
|
JP5654352B2
(ja)
*
|
2007-11-09 |
2015-01-14 |
ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム |
ｍｉＲ−１５ファミリーのマイクロＲＮＡによる心筋細胞生存及び心臓修復の調節
|
|
US8071562B2
(en)
|
2007-12-01 |
2011-12-06 |
Mirna Therapeutics, Inc. |
MiR-124 regulated genes and pathways as targets for therapeutic intervention
|
|
CA2718520C
(en)
|
2008-03-17 |
2020-01-07 |
The Board Of Regents Of The University Of Texas System |
Identification of micro-rnas involved in neuromuscular synapse maintenance and regeneration
|
|
US8258111B2
(en)
|
2008-05-08 |
2012-09-04 |
The Johns Hopkins University |
Compositions and methods related to miRNA modulation of neovascularization or angiogenesis
|
|
EP2358912B1
(en)
|
2008-10-30 |
2016-10-12 |
Caris Life Sciences Switzerland Holdings GmbH |
Methods for assessing rna patterns
|
|
EP2364367B8
(en)
|
2008-11-10 |
2017-08-23 |
Battelle Memorial Institute |
Method utilizing microrna for detecting interstitial lung disease
|
|
GB2463401B
(en)
|
2008-11-12 |
2014-01-29 |
Caris Life Sciences Luxembourg Holdings S A R L |
Characterizing prostate disorders by analysis of microvesicles
|
|
WO2011109440A1
(en)
|
2010-03-01 |
2011-09-09 |
Caris Life Sciences Luxembourg Holdings |
Biomarkers for theranostics
|
|
WO2010055487A2
(en)
*
|
2008-11-13 |
2010-05-20 |
Koninklijke Philips Electronics N.V. |
Compositions and methods for micro-rna expession profiling of colorectal cancer
|
|
WO2011127219A1
(en)
|
2010-04-06 |
2011-10-13 |
Caris Life Sciences Luxembourg Holdings |
Circulating biomarkers for disease
|
|
WO2011150855A1
(en)
*
|
2010-06-04 |
2011-12-08 |
Fudan University |
Micro-rna biomarkers and methods for diagnosis of early colorectal carcinoma and high-grade adenoma
|
|
NZ704322A
(en)
|
2010-07-06 |
2016-07-29 |
Interna Technologies Bv |
Mirna and its diagnostic and therapeutic uses in diseases or conditions associated with melanoma, or in diseases or conditions associated with activated braf pathway
|
|
CN103221542A
(zh)
*
|
2010-09-27 |
2013-07-24 |
萨班哲大学 |
miRNA用于诊断、预防、治疗和追踪涉及巨自噬异常的疾病的用途
|
|
EP2474617A1
(en)
|
2011-01-11 |
2012-07-11 |
InteRNA Technologies BV |
Mir for treating neo-angiogenesis
|
|
WO2013040251A2
(en)
|
2011-09-13 |
2013-03-21 |
Asurgen, Inc. |
Methods and compositions involving mir-135b for distinguishing pancreatic cancer from benign pancreatic disease
|
|
US9850541B2
(en)
|
2011-12-19 |
2017-12-26 |
Valley Health System |
Methods and kits for detecting subjects at risk of having cancer
|
|
WO2013101783A2
(en)
|
2011-12-30 |
2013-07-04 |
Bio-Rad Laboratories, Inc. |
Methods and compositions for performing nucleic acid amplification reactions
|
|
WO2013170146A1
(en)
|
2012-05-10 |
2013-11-14 |
Uab Research Foundation |
Methods and compositions for modulating mir-204 activity
|
|
US9163235B2
(en)
|
2012-06-21 |
2015-10-20 |
MiRagen Therapeutics, Inc. |
Inhibitors of the miR-15 family of micro-RNAs
|
|
WO2014043159A1
(en)
*
|
2012-09-11 |
2014-03-20 |
New York University |
Sera based mirnas as non-invasive biomarkers in melanoma
|
|
WO2014093924A1
(en)
|
2012-12-13 |
2014-06-19 |
Moderna Therapeutics, Inc. |
Modified nucleic acid molecules and uses thereof
|
|
WO2014081507A1
(en)
|
2012-11-26 |
2014-05-30 |
Moderna Therapeutics, Inc. |
Terminally modified rna
|
|
EP3363902B1
(en)
*
|
2012-12-06 |
2019-11-27 |
Sigma Aldrich Co. LLC |
Crispr-based genome modification and regulation
|
|
US20140200261A1
(en)
|
2013-01-17 |
2014-07-17 |
Moderna Therapeutics, Inc. |
Signal-sensor polynucleotides for the alteration of cellular phenotypes
|
|
KR101501562B1
(ko)
*
|
2013-04-05 |
2015-03-11 |
연세대학교 산학협력단 |
췌장암 진단 마커를 검출하는 방법
|
|
US20150018230A1
(en)
*
|
2013-06-11 |
2015-01-15 |
Indiana University Research And Technology Corp. |
PLASMA miRNA SIGNATURE FOR THE ACCURATE DIAGNOSIS OF PANCREATIC DUCTAL ADENOCARCINOMA
|
|
JP6611411B2
(ja)
*
|
2013-12-05 |
2019-11-27 |
東レ株式会社 |
膵臓がんの検出キット及び検出方法
|
|
EP3108012A4
(en)
|
2014-02-18 |
2017-10-11 |
Baylor Research Institute |
Mir-320e and colorectal cancer
|
|
EP3115467B1
(en)
|
2014-03-04 |
2019-01-02 |
Hiroshima University |
Method for assisting detection of pancreatic cancer
|
|
KR102680815B1
(ko)
*
|
2014-05-30 |
2024-07-03 |
국립연구개발법인 고쿠리츠간켄큐센터 |
췌장암의 검출 키트 또는 디바이스 및 검출 방법
|
|
US9623040B2
(en)
|
2014-07-14 |
2017-04-18 |
The Board Of Trustees Of The Leland Stanford Junior University |
Immunomodulation by controlling expression levels of microRNAs in dendritic cells
|
|
EP3461904A1
(en)
|
2014-11-10 |
2019-04-03 |
ModernaTX, Inc. |
Alternative nucleic acid molecules containing reduced uracil content and uses thereof
|
|
JP2016123340A
(ja)
*
|
2014-12-26 |
2016-07-11 |
株式会社エバンス |
膵癌治療感受性の診断方法及び膵癌治療感受性の増強剤
|
|
EP3405579A1
(en)
|
2016-01-22 |
2018-11-28 |
Modernatx, Inc. |
Messenger ribonucleic acids for the production of intracellular binding polypeptides and methods of use thereof
|
|
EP3988668A3
(en)
|
2016-03-31 |
2022-06-29 |
Toray Industries, Inc. |
Kit or device for detecting early stage pancreatic cancer or pancreatic cancer precursor lesions and detection method therefor
|
|
EP3443001B1
(en)
|
2016-04-11 |
2025-04-30 |
Obsidian Therapeutics, Inc. |
REGULATED BIOCIRCUIT SYSTEMS
|
|
KR102469450B1
(ko)
|
2016-05-18 |
2022-11-22 |
모더나티엑스, 인크. |
인터류킨-12 (il12)를 코딩하는 폴리뉴클레오티드 및 그의 용도
|
|
WO2017218704A1
(en)
|
2016-06-14 |
2017-12-21 |
Modernatx, Inc. |
Stabilized formulations of lipid nanoparticles
|
|
TW201805000A
(zh)
*
|
2016-06-20 |
2018-02-16 |
庫拉腫瘤技術股份有限公司 |
利用erk抑制劑之鱗狀細胞癌之治療
|
|
EP3478828B1
(en)
|
2016-06-29 |
2024-09-04 |
CRISPR Therapeutics AG |
Materials and methods for treatment of friedreich ataxia and other related disorders
|
|
US11427838B2
(en)
|
2016-06-29 |
2022-08-30 |
Vertex Pharmaceuticals Incorporated |
Materials and methods for treatment of myotonic dystrophy type 1 (DM1) and other related disorders
|
|
WO2018002762A1
(en)
|
2016-06-29 |
2018-01-04 |
Crispr Therapeutics Ag |
Materials and methods for treatment of amyotrophic lateral sclerosis (als) and other related disorders
|
|
AU2017292173B2
(en)
|
2016-07-06 |
2022-01-13 |
Vertex Pharmaceuticals Incorporated |
Materials and methods for treatment of pain related disorders
|
|
JP7305534B2
(ja)
|
2016-07-06 |
2023-07-10 |
バーテックス ファーマシューティカルズ インコーポレイテッド |
疼痛関連障害を処置するための物質及び方法
|
|
SG11201903674YA
(en)
|
2016-10-26 |
2019-05-30 |
Modernatx Inc |
Messenger ribonucleic acids for enhancing immune responses and methods of use thereof
|
|
US11584932B2
(en)
|
2016-11-01 |
2023-02-21 |
The Research Foundation For The State University Of New York |
5-halouracil-modified microRNAs and their use in the treatment of cancer
|
|
US11583504B2
(en)
|
2016-11-08 |
2023-02-21 |
Modernatx, Inc. |
Stabilized formulations of lipid nanoparticles
|
|
JP2020514321A
(ja)
|
2017-02-01 |
2020-05-21 |
モデルナティーエックス， インコーポレイテッド |
活性化がん遺伝子変異ペプチドをコードする免疫調節治療ｍＲＮＡ組成物
|
|
US11559588B2
(en)
|
2017-02-22 |
2023-01-24 |
Crispr Therapeutics Ag |
Materials and methods for treatment of Spinocerebellar Ataxia Type 1 (SCA1) and other Spinocerebellar Ataxia Type 1 Protein (ATXN1) gene related conditions or disorders
|
|
WO2018154462A2
(en)
|
2017-02-22 |
2018-08-30 |
Crispr Therapeutics Ag |
Materials and methods for treatment of spinocerebellar ataxia type 2 (sca2) and other spinocerebellar ataxia type 2 protein (atxn2) gene related conditions or disorders
|
|
JP2020508056A
(ja)
|
2017-02-22 |
2020-03-19 |
クリスパー・セラピューティクス・アクチェンゲゼルシャフトＣＲＩＳＰＲ Ｔｈｅｒａｐｅｕｔｉｃｓ ＡＧ |
遺伝子編集のための組成物および方法
|
|
US20200040061A1
(en)
|
2017-02-22 |
2020-02-06 |
Crispr Therapeutics Ag |
Materials and methods for treatment of early onset parkinson's disease (park1) and other synuclein, alpha (snca) gene related conditions or disorders
|
|
EP3585899A1
(en)
|
2017-02-22 |
2020-01-01 |
CRISPR Therapeutics AG |
Materials and methods for treatment of primary hyperoxaluria type 1 (ph1) and other alanine-glyoxylate aminotransferase (agxt) gene related conditions or disorders
|
|
US20200131498A1
(en)
|
2017-06-14 |
2020-04-30 |
Modernatx, Inc. |
Polynucleotides encoding methylmalonyl-coa mutase
|
|
US10636512B2
(en)
|
2017-07-14 |
2020-04-28 |
Cofactor Genomics, Inc. |
Immuno-oncology applications using next generation sequencing
|
|
WO2019046809A1
(en)
|
2017-08-31 |
2019-03-07 |
Modernatx, Inc. |
METHODS OF MANUFACTURING LIPID NANOPARTICLES
|
|
MA50877A
(fr)
|
2017-11-21 |
2020-09-30 |
Bayer Healthcare Llc |
Matériaux et méthodes pour le traitement de la rétinite pigmentaire autosomique dominante
|
|
JP7298914B2
(ja)
*
|
2017-12-13 |
2023-06-27 |
国立大学法人広島大学 |
膵がんの検出を補助する方法
|
|
WO2019123429A1
(en)
|
2017-12-21 |
2019-06-27 |
Casebia Therapeutics Llp |
Materials and methods for treatment of usher syndrome type 2a
|
|
JP2021512090A
(ja)
|
2018-01-30 |
2021-05-13 |
モデルナティーエックス， インコーポレイテッド |
免疫細胞に薬剤を送達するための組成物及び方法
|
|
EP3773745A1
(en)
|
2018-04-11 |
2021-02-17 |
ModernaTX, Inc. |
Messenger rna comprising functional rna elements
|
|
WO2019241315A1
(en)
|
2018-06-12 |
2019-12-19 |
Obsidian Therapeutics, Inc. |
Pde5 derived regulatory constructs and methods of use in immunotherapy
|
|
CN113271926A
(zh)
|
2018-09-20 |
2021-08-17 |
摩登纳特斯有限公司 |
脂质纳米颗粒的制备及其施用方法
|
|
WO2020086742A1
(en)
|
2018-10-24 |
2020-04-30 |
Obsidian Therapeutics, Inc. |
Er tunable protein regulation
|
|
JP7635131B2
(ja)
|
2019-01-31 |
2025-02-25 |
モデルナティエックス インコーポレイテッド |
脂質ナノ粒子の調製方法
|
|
KR20210149251A
(ko)
|
2019-03-08 |
2021-12-08 |
옵시디안 테라퓨틱스, 인크. |
조율가능한 조절을 위한 인간 탄산 무수화효소 2 조성물 및 방법
|
|
WO2020218489A1
(ja)
*
|
2019-04-26 |
2020-10-29 |
国立大学法人大阪大学 |
トンネル電流を使用したマイクロｒｎａ解析
|
|
WO2020263985A1
(en)
|
2019-06-24 |
2020-12-30 |
Modernatx, Inc. |
Messenger rna comprising functional rna elements and uses thereof
|
|
EP3987027A1
(en)
|
2019-06-24 |
2022-04-27 |
ModernaTX, Inc. |
Endonuclease-resistant messenger rna and uses thereof
|
|
WO2021046451A1
(en)
|
2019-09-06 |
2021-03-11 |
Obsidian Therapeutics, Inc. |
Compositions and methods for dhfr tunable protein regulation
|
|
US20230285297A1
(en)
|
2020-01-31 |
2023-09-14 |
Modernatx, Inc. |
Methods of preparing lipid nanoparticles
|
|
US11965162B2
(en)
*
|
2020-04-16 |
2024-04-23 |
The Johns Hopkins University |
MicroRNA and inhibitors thereof and methods of treatment
|
|
WO2021262919A2
(en)
|
2020-06-26 |
2021-12-30 |
The Research Foundation For The State University Of New York |
5-halouracil-modified micrornas and their use in the treatment of cancer
|
|
JP7802367B2
(ja)
*
|
2020-07-16 |
2026-01-20 |
学校法人 久留米大学 |
膵臓がんのバイオマーカーとしてのマイクロｒｎａの使用
|
|
JP2023535225A
(ja)
|
2020-07-24 |
2023-08-16 |
ストランド セラピューティクス インコーポレイテッド |
改変ヌクレオチドを含む脂質ナノ粒子
|
|
KR20230167008A
(ko)
|
2020-08-06 |
2023-12-07 |
모더나티엑스, 인크. |
지질 나노입자의 제조 방법
|
|
US20240166707A1
(en)
|
2021-01-08 |
2024-05-23 |
Strand Therapeutics Inc. |
Expression constructs and uses thereof
|
|
CA3171589A1
(en)
|
2021-05-03 |
2022-11-03 |
Moritz THRAN |
Improved nucleic acid sequence for cell type specific expression
|
|
WO2023166425A1
(en)
|
2022-03-01 |
2023-09-07 |
Crispr Therapeutics Ag |
Methods and compositions for treating angiopoietin-like 3 (angptl3) related conditions
|
|
EP4514328A1
(en)
|
2022-04-26 |
2025-03-05 |
Strand Therapeutics Inc. |
Lipid nanoparticles comprising venezuelan equine encephalitis (vee) replicon and uses thereof
|
|
EP4561547A1
(en)
|
2022-07-29 |
2025-06-04 |
ModernaTX, Inc. |
Lipid nanoparticle compositions comprising phospholipid derivatives and related uses
|
|
WO2024026475A1
(en)
|
2022-07-29 |
2024-02-01 |
Modernatx, Inc. |
Compositions for delivery to hematopoietic stem and progenitor cells (hspcs) and related uses
|
|
WO2024026482A1
(en)
|
2022-07-29 |
2024-02-01 |
Modernatx, Inc. |
Lipid nanoparticle compositions comprising surface lipid derivatives and related uses
|
|
EP4703374A1
(en)
|
2023-04-28 |
2026-03-04 |
Shenzhen Shenxin Biotechnology Co., Ltd. |
Modified delivery vector and use thereof
|
|
EP4727914A1
(en)
|
2023-06-14 |
2026-04-22 |
ModernaTX, Inc. |
Compounds and compositions for delivery of therapeutic agents
|
|
WO2025160381A1
(en)
|
2024-01-26 |
2025-07-31 |
Modernatx, Inc. |
Methods of preparing lipid nanoparticles
|
|
WO2025166202A1
(en)
|
2024-01-31 |
2025-08-07 |
Modernatx, Inc. |
Lipid nanoparticle compositions comprising sialic acid derivatives and the uses thereof
|
|
ES3048857A1
(es)
*
|
2024-06-10 |
2025-12-11 |
Fundacion Para La Investig E Innovacion Biosanitaria Del Principado De Asturias Finba |
FIRMA DE miRNA UTILES EN LA DISCRIMINACION DE TUMORES
|
|
CN119391860B
(zh)
*
|
2024-12-25 |
2025-03-21 |
慧算基因科技(上海)有限公司 |
一种用于胰腺癌术后mrd检测及动态监测的引物探针组合物、试剂盒及应用
|